In agreement with our results, the radiosensitization effects of the HDAC inhibitor were previously reported in various cancer models (19), and more recently, cotreatment with vorinostat improved the response to the radiolabeled peptide ligand 212Pb-DOTA-MC1L in mice bearing human melanoma xenografts (33). Here, HDAC9 is linked to cancer.